1. EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH‐RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME. (12th June 2019) Authors: Eskelund, C.W.; Kolstad, A.; Glimelius, I.; Räty, R.; Gjerdrum, L.R.; Sonnevi, K.; Josefsson, P.; Nilsson‐Ehle, H.; Bentzen, H.; Fagerli, U.; Kuittinen, O.; Haaber, J.; Pedersen, L.B.; Larsen, M.T.; Geisler, C.H.; Hutchings, M.; Jerkeman, M.; Grønbæk, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA. (23rd June 2022) Authors: Blum, M. K.; Hansen, S. V.; Cédile, O.; Haaber, J.; Chen, L.; Kassem, M.; Abildgaard, N.; Hansen, M. H.; Nyvold, C. G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 2028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗